Literature DB >> 20234390

TTR familial amyloid polyneuropathy: does a mitochondrial polymorphism entirely explain the parent-of-origin difference in penetrance?

Bernard Bonaïti1, Malin Olsson, Urban Hellman, Ole Suhr, Catherine Bonaïti-Pellié, Violaine Planté-Bordeneuve.   

Abstract

The Val30Met transthyretin familial amyloid polyneuropathy (TTR-V30M-FAP) is the most frequent familial amyloidosis, with autosomal dominant transmission. This severe disease shows important differences in age of onset and penetrance. Recently, a difference in penetrance according to the gender of the transmitting parent was elicited in different geographic areas with a higher penetrance in case of maternal transmission of the trait. In addition, differences in mitochondrial haplogroup distribution in early and late onset Swedish and French cases of TTR-V30M-FAP suggested that a polymorphism of mitochondrial DNA could be one underlying mechanism of the phenotypic variation. We further investigated this hypothesis by modeling the penetrance function with a parent-of-origin and/or a mitochondrial polymorphism effect in samples of Portuguese (n=33) and Swedish families (n=86) with TTR-V30M-FAP in which several individuals had been tested for mitochondrial haplogroups. Our analysis showed that a mitochondrial polymorphism effect was sufficient to explain the observed difference in penetrance according to gender of the transmitting parent in the Portuguese sample, whereas, in the Swedish sample, a clear residual parent-of-origin effect remained. This study further supported the role of a mitochondrial polymorphism effect that might induce a higher penetrance in case of maternal inheritance of the disease. In clinical practice, these results might help to better delineate the individual disease risk and have a significant impact on the management of both patients and carriers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20234390      PMCID: PMC2987385          DOI: 10.1038/ejhg.2010.36

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  21 in total

1.  Genetic study of transthyretin amyloid neuropathies: carrier risks among French and Portuguese families.

Authors:  V Planté-Bordeneuve; J Carayol; A Ferreira; D Adams; F Clerget-Darpoux; M Misrahi; G Said; C Bonaïti-Pellié
Journal:  J Med Genet       Date:  2003-11       Impact factor: 6.318

2.  Parent-of-origin effect in transthyretin related amyloid polyneuropathy.

Authors:  Bernard Bonaïti; Flora Alarcon; Catherine Bonaïti-Pellié; Violaine Planté-Bordeneuve
Journal:  Amyloid       Date:  2009       Impact factor: 7.141

3.  A general model for the genetic analysis of pedigree data.

Authors:  R C Elston; J Stewart
Journal:  Hum Hered       Date:  1971       Impact factor: 0.444

Review 4.  Mitochondrial DNA variation in human evolution and disease.

Authors:  D C Wallace; M D Brown; M T Lott
Journal:  Gene       Date:  1999-09-30       Impact factor: 3.688

5.  Hereditary generalized amyloidosis with polyneuropathy. Clinicopathological study of 65 Japanese patients.

Authors:  S Ikeda; N Hanyu; M Hongo; J Yoshioka; H Oguchi; N Yanagisawa; T Kobayashi; H Tsukagoshi; N Ito; T Yokota
Journal:  Brain       Date:  1987-04       Impact factor: 13.501

6.  Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form.

Authors:  Haruki Koike; Ken-ichiro Misu; Shu-ichi Ikeda; Yukio Ando; Masamitsu Nakazato; Eiko Ando; Masahiko Yamamoto; Naoki Hattori; Gen Sobue
Journal:  Arch Neurol       Date:  2002-11

Review 7.  Mitochondrial uncoupling proteins--facts and fantasies.

Authors:  P Jezek; M Zácková; M Růzicka; E Skobisová; M Jabůrek
Journal:  Physiol Res       Date:  2004       Impact factor: 1.881

8.  Degradation of misfolded proteins prevents ER-derived oxidative stress and cell death.

Authors:  Cole M Haynes; Eric A Titus; Antony A Cooper
Journal:  Mol Cell       Date:  2004-09-10       Impact factor: 17.970

9.  Transthyretin gene analysis in European patients with suspected familial amyloid polyneuropathy.

Authors:  M M Reilly; D Adams; D R Booth; M B Davis; G Said; M Laubriat-Bianchin; M B Pepys; P K Thomas; A E Harding
Journal:  Brain       Date:  1995-08       Impact factor: 13.501

10.  Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate.

Authors:  G Holmgren; P M Costa; C Andersson; K Asplund; L Steen; L Beckman; P O Nylander; A Teixeira; M J Saraiva; P P Costa
Journal:  J Med Genet       Date:  1994-05       Impact factor: 6.318

View more
  22 in total

1.  Non-coding variants contribute to the clinical heterogeneity of TTR amyloidosis.

Authors:  Andrea Iorio; Antonella De Lillo; Flavio De Angelis; Marco Di Girolamo; Marco Luigetti; Mario Sabatelli; Luca Pradotto; Alessandro Mauro; Anna Mazzeo; Claudia Stancanelli; Federico Perfetto; Sabrina Frusconi; Filomena My; Dario Manfellotto; Maria Fuciarelli; Renato Polimanti
Journal:  Eur J Hum Genet       Date:  2017-06-21       Impact factor: 4.246

Review 2.  The emergence of the mitochondrial genome as a partial regulator of nuclear function is providing new insights into the genetic mechanisms underlying age-related complex disease.

Authors:  Martin P Horan; David N Cooper
Journal:  Hum Genet       Date:  2013-12-04       Impact factor: 4.132

3.  Risks inherent to mitochondrial replacement.

Authors:  Edward H Morrow; Klaus Reinhardt; Jonci N Wolff; Damian K Dowling
Journal:  EMBO Rep       Date:  2015-03-25       Impact factor: 8.807

Review 4.  Transthyretin Cardiac Amyloidosis in Black Americans.

Authors:  Keyur B Shah; Anit K Mankad; Adam Castano; Olakunle O Akinboboye; Phillip B Duncan; Icilma V Fergus; Mathew S Maurer
Journal:  Circ Heart Fail       Date:  2016-06       Impact factor: 8.790

Review 5.  Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs.

Authors:  Adam Castaño; Brian M Drachman; Daniel Judge; Mathew S Maurer
Journal:  Heart Fail Rev       Date:  2015-03       Impact factor: 4.214

Review 6.  Mitochondrial Replacement Therapy: Are Mito-nuclear Interactions Likely To Be a Problem?

Authors:  Adam Eyre-Walker
Journal:  Genetics       Date:  2017-04       Impact factor: 4.562

7.  Mitonuclear linkage disequilibrium in human populations.

Authors:  Daniel B Sloan; Peter D Fields; Justin C Havird
Journal:  Proc Biol Sci       Date:  2015-09-22       Impact factor: 5.349

8.  Does transthyretin function as one of contributors for preeclampsia?

Authors:  Yuxuan Chen; Zhenyu Zhang
Journal:  Med Hypotheses       Date:  2010-09-09       Impact factor: 1.538

9.  A Missense Variant p.Ala117Ser in the Transthyretin Gene of a Han Chinese Family with Familial Amyloid Polyneuropathy.

Authors:  Qian Chen; Lamei Yuan; Xiong Deng; Zhijian Yang; Shengwang Zhang; Sheng Deng; Hongwei Lu; Hao Deng
Journal:  Mol Neurobiol       Date:  2017-07-31       Impact factor: 5.590

Review 10.  Guideline of transthyretin-related hereditary amyloidosis for clinicians.

Authors:  Yukio Ando; Teresa Coelho; John L Berk; Márcia Waddington Cruz; Bo-Göran Ericzon; Shu-ichi Ikeda; W David Lewis; Laura Obici; Violaine Planté-Bordeneuve; Claudio Rapezzi; Gerard Said; Fabrizio Salvi
Journal:  Orphanet J Rare Dis       Date:  2013-02-20       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.